Nelli Morgulchik

building with the people creating the sci-fi future 🔮

📍 Israel🔄 Updated September 2026💼 2 investments📅 2 years investing🗓 Last invested Jan 2025
VC🌍 Israel
2
Total investments
0
Early stage
0
Mid stage
0
Late stage
2y
Years active

Portfolio

1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Angel Investor
2025
This is a catchall company for the doers, the thinkers, and the innovators.
Experience · 5 entries
All (5)
Investments (2)
Founder (1)
2025
Angel Investor
2025
This is a catchall company for the doers, the thinkers, and the innovators.
Co-Founder
2025
We believe there has never been a more exciting time to build in bio - were here to support those who are. future.bio is here to provide a different kind of community. One built for and around founders.
2024
Investor
2024
Hummingbird Ventures is an agile investor in entrepreneurial genius. We value emotional intelligence as much as data, growing internal culture as much as growing revenue, and forming strong, personal bonds with founders. Often the first institutional investor, we’ve helped start-ups scale from zero to category-defining multi-billion dollar businesses across 3 continents. We work best with outsiders who challenge industry boundaries and conventions, transforming tiny miracles into impactful companies. Hummingbird Ventures teamed up with transformative companies, including Deliveroo, Showpad, Kraken, Peak Games, Amplidata, Gram Games, Shutl, Merlin, Billiontoone and many others.
2021
Strategy & Partnerships Associate
2021
Hertility is a women’s health company built by women, for women. We’re shaping the future of reproductive healthcare by pioneering unique diagnostic testing that provides data-driven and advanced insights into reproductive health, fertility decline and the onset of menopause. We provide expert advice, education and access to care - all from the comfort of your home. Our research trials are a step towards fixing the currently flawed system. 31% of women will suffer from a reproductive health issue at some point and through our research, we aim to reduce the time to diagnosis through advanced at-home testing and specialist gynaecological care. We tailor pathways to the individuals reproductive goals, whether it be to explore their ovarian health and fertility options or overall hormonal health, such as confirming a PCOS diagnosis. Currently, we can diagnose 9 of the most common gynae pathologies which may lead to reduced fertility and signpost gynae cancers. Ultimately, our aim is to change attitudes around reproductive health, both for individuals and in the workplace, and to encourage women to be proactive by tracking their reproductive health. We’re calling this the Reproductive Revolution!
2020
Analyst
2020
CBPartners is a global consultancy committed to providing unparalleled strategic support to pharmaceutical companies, biopharmaceutical companies, medical device companies, and government health authorities. The firm has three practice areas: Value, Access, and Pricing Commercial Strategic Planning Government Policy Advisory The firms largest office is in New York City, with European regional headquarters in London, and Western USA regional headquarters in San Francisco.